Switching from Odefsey to Biktarvy in HIV Patients
Key Requirements Before Switching
- The American Medical Association recommends reviewing a patient's complete antiretroviral treatment history, prior resistance testing results, comorbidities, potential drug-drug interactions, and hepatitis B coinfection status before switching from Odefsey to Biktarvy 1, 2
Why This Switch Makes Clinical Sense
Superior Resistance Barrier
- Switching from a low-barrier regimen (rilpivirine) to a high-barrier regimen (bictegravir) is generally safe even without complete resistance history, according to the Journal of the American Medical Association 3, 5
- The International Antiviral Society-USA guidelines support switching from a low-barrier to a high-barrier regimen for improved resistance barrier 3, 5
Improved Safety Profile
- The switch from TDF (in Odefsey) to TAF (in Biktarvy) offers superior renal and bone safety based on consistent surrogate marker data, as recommended by the American Medical Association 3, 4
- TAF demonstrates better bone mineral density preservation and reduced renal toxicity markers compared to TDF, according to the Journal of the American Medical Association 3, 4
Switching Protocol
Post-Switch Monitoring
- The American Medical Association recommends checking HIV-1 RNA at 1 month after switching to ensure continued virologic suppression 1, 2
- Viral load assessment at 1 month post-switch is mandatory, and continue monitoring every 3 months for the first year, as suggested by the Journal of the American Medical Association 1, 2